Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Sun Yat-sen University
Modality
UNKNOWN
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04395339CT.gov GM1 Prophylaxis for WBRT Related Cognitive Dysfunction | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Radiation Injury
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Monosialotetrahexosylganglioside (this asset) | Sun Yat-sen University | P3 | CCC · 52 |
| Nivestim | IRCCS San Raffaele | P3 | BB |
| Etoposide | Sun Yat-sen University | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Sun Yat-sen University | P3 | BB |
| Amifostine | Alliance for Clinical Trials in Oncology | P3 | BB |
| Carboplatin | Sun Yat-sen University | P3 | BB |
| Mometasone | North Central Cancer Treatment Group | P3 | B |
| Cetuximab | Radiation Therapy Oncology Group | P3 | B |
| Cicaderma | Centre Leon Berard | P3 | B |
+29 more in the Radiation Injury cohort
Other indications for Monosialotetrahexosylganglioside
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P3 | CCC · 54 |
| Cognitive Disorder | — | P3 | CCC · 52 |
| Metastatic Malignant Neoplasm In The Brain | — | P3 | CCC · 49 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Monosialotetrahexosylganglioside in Radiation Injury. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/monosialotetrahexosylganglioside-radiation-injury
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →